CELL INTELLIGENCE · 肿瘤细胞治疗研究

AI 驱动的生物治疗：输血医学与生物治疗交叉领域的人工智能与信息学

AI-powered biotherapies: Artificial intelligence and informatics at the intersection of transfusion medicine and biotherapies.

AI与信息学正被定位为开启精准、数据驱动生物治疗新时代的力量。

肿瘤学先进基因编辑技术：机制、应用与临床实施

Advanced gene editing technologies for oncology mechanisms, applications, and clinical implementation.

克服卵巢癌治疗耐药：从分子机制到新兴治疗策略

Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies.

用于乳腺癌治疗的可注射水凝胶：从肿瘤微环境响应性与主动靶向药物递送到免疫治疗与诊疗一体化

Injectable Hydrogels for Breast Cancer Therapy: From Tumor Microenvironment-Responsive and Actively Targeted Drug Delivery to Immunotherapy and Theran

先导编辑实现具备临床免疫抑制的可药物控制 T 细胞疗法

Prime editing enables drug-controllable T-cell therapies with clinical immunosuppression.

CAR-T 细胞疗法：生产平台与临床结果

CAR-T Cell Therapy: Manufacturing Platforms and Clinical Consequences.

基因阻断 PD-1/PD-L1 作为肿瘤免疫检查点阻断的替代手段：综述

Genetic Interruption of PD-1/PD-L1 as an Alternative Means for Immune Checkpoint Blockade in Cancer: A Review.

CAR-T 细胞基因治疗的综合评价：追溯其革命性临床突破与迈向下一代工程的进展

A Comprehensive Evaluation of CAR-T Cell Gene Therapy, Tracing its Revolutionary Clinical Breakthroughs and Advancements Towards Next-Generation Engin

基于这些进展，我们假设 CAR-T 疗法正经历从单靶点细胞毒性向多功能、可编程框架的范式转变，该框架能够克服耐药性、增强安全性，并实现实体瘤的有效渗透。

通往体内 CAR-T 成功之路：有前景的病毒载体与非病毒载体比较

On the road to in vivo CAR-T success: Comparing promising viral and non-viral vectors.

一种工程化腺相关病毒变体实现人 T 细胞的高效基因编辑

An Engineered Adeno-Associated Virus Variant Enables Efficient Gene Editing in Human T Cells.